Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Common Equity (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Common Equity for 6 consecutive years, with $567.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 27.09% to $567.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $567.1 million, a 27.09% decrease, with the full-year FY2025 number at $567.1 million, down 27.09% from a year prior.
  • Common Equity was $567.1 million for Q4 2025 at Relay Therapeutics, down from $607.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $999.8 million in Q3 2022 to a low of $567.1 million in Q4 2025.
  • A 5-year average of $761.1 million and a median of $764.9 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 462.14% in 2021, then dropped 27.56% in 2025.
  • Relay Therapeutics' Common Equity stood at $897.8 million in 2021, then rose by 5.84% to $950.2 million in 2022, then dropped by 20.86% to $752.0 million in 2023, then grew by 3.43% to $777.8 million in 2024, then decreased by 27.09% to $567.1 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Common Equity are $567.1 million (Q4 2025), $607.7 million (Q3 2025), and $665.7 million (Q2 2025).